Updated on 24 Dec 2016
Your place to Learn and Earn
StockMarketIndian.com
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but www.stockmarketindian.com does not warrant or guarantee their accuracy or date.
www.stockmarketindian.com takes no responsibility for any investment decisions based on recommendations provided on website.
Financial contents like Technical charts, historical charts and quotes are taken from NSE and Yahoo sites.
Note - All quotes are delayed by 15 minutes and unless specified.

Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to www.stockmarketindian.com and any financial deal should be done on their own sole responsibility.
Please read our before using any material or advice given at www.stockmarketindian.com

Cipla up 5% on UK MHRA approval for generic asthma drug
Latest posts
Cipla gained 5% to Rs 589, bouncing back 6.5% from intra-day low on the BSE, after the pharmaceutical company said its flagship product Sereflo received final approval from UK health regulator.

“The company has received a final approval for its lead metered dose inhaler (MDI) product Fluticasone + Salmeterol (Sereflo) from Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) for its partner in the UK," Cipla said in a release.

According to IMS Health, Seretide inhaler, for the aforementioned strengths, had UK sales of approximately $ 278 million for the 12 month period ending June 2016.

At 03:11 pm; the stock was up 3.5% at Rs 580, after hitting an intra-day low of Rs 553 on the BSE. The trading volumes on the counter more than doubled with a combined 2.32 million shares changed hands on the BSE and NSE so far.